Back to search

Peptide record

TPDB03300

Antibacterial Anticancer Antifungal Antiparasitic Antiviral Toxicity standard
24 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB03300
Antibacterial Anticancer Antifungal Antiparasitic Antiviral Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 Peptipedia Antifungipept CAFPdb dbAMP dbAMP 3.0 i2APP pep-lab ToxinPred 3.0
standard
No
A 24-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, Peptipedia, Antifungipept, and other sources, with an available 3D structural model.
Sequence
GRGREFMSNLKEKLSGVKEKMKNS
Physicochemical Analysis
C116H201N37O36S2
ADCQHIPTWY
K
2754.22
10.69
7
3
6
+4
11.25
-1.300
44.58
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
0
0.00
5
Residue Composition
number
0
A
2
R
2
N
0
D
0
C
3
E
0
Q
3
G
0
H
0
I
2
L
5
K
2
M
1
F
0
P
3
S
0
T
0
W
0
Y
1
V
Amino Acid Distribution
A: 0 R: 2 N: 2 D: 0 C: 0 E: 3 Q: 0 G: 3 H: 0 I: 0 L: 2 K: 5 M: 2 F: 1 P: 0 S: 3 T: 0 W: 0 Y: 0 V: 1
Chemical Descriptors
24
C116H201N37O36S2
2754.22
10.69
+4
11.25
-1.300
Evidence Records 3 records
Evidence 1 Activity

Activity

Toxicity
Hemolytic Cytotoxic
- | NA | target cell: Mouse erythrocytes

Target

Mouse erythrocytes

Source & Reference

NA
DBAASP
Characterization of two linear cationic antimalarial peptides in the scorpion Mesobuthus eupeus. | Biochimie | 2010
Evidence 2 Activity

Activity

17% Killing
Toxicity
50 µM
Cytotoxic
17% Killing | 50 | µM | target cell: Human GC-2 cells

Target

Human GC-2 cells

Source & Reference

NA
DBAASP
Characterization of two linear cationic antimalarial peptides in the scorpion Mesobuthus eupeus. | Biochimie | 2010
Evidence 3 Activity

Activity

Toxicity
Hemolytic
Hemolytic_activity: [Ref.20097251]Non-hemolytic effect against mouse erythrocytes even at 100 µM

Target

erythrocytes

Source & Reference

NA
DRAMP
Biochimie. 2010 Apr 92(4):350-359.